Kedrion took part in the conference entitled “The role of plasma for rare diseases: a commitment that saves lives”, organized by the Luciano Ciocchetti, Vice President of the Social Affairs Committee of the Italian Chamber and held on November 27 in Rome at the Sala del Refettorio of the Chamber of Deputies. The event brought together institutions, industry representatives and the medical-scientific community to discuss the challenges and opportunities in pharmaceutical governance and therapeutic perspectives for patients suffering from rare diseases.
Speaking at the event, Kedrion CEO Ugo Di Francesco said: “For a company like Kedrion, specialized in the production of plasma-derived medicines, optimizing plasma resources is increasingly crucial to identify new potential therapeutic opportunities, particularly for orphan diseases: as also demonstrated by our commitment to the treatment of Congenital Plasminogen Deficiency, one of the diseases at the center of today’s meeting”.
The event included two round tables that explored the specificities of ultra-rare diseases and the priorities for institutions.
“As an integral part of the pharmaceutical chain, we work tirelessly – continued Ugo Di Francesco – to provide increasingly effective and personalized solutions to a growing number of patients around the world. In Italy, the commitment by institutions is significant, but more can always be done. And to achieve this, we need to network: today’s meeting makes us confident and optimistic about the possibility of strengthening discussions and constructive dialogue with patient and donor associations, the medical-scientific community and political decision-makers to improve pharmaceutical governance”.
With a global presence and a strong focus on rare and ultra-rare diseases, Kedrion continues to focus on the production of plasma-derived therapies, underlining the value of the plasma resource and its crucial role in the treatment of rare and serious diseases.
